Carglumic acid (Ucedane®) is indicated for the treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/05/2022|
|Rapid review completed||21/06/2022|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that carglumic acid (Ucedane®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.